SAN DIEGO, March 13, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Nick Boyle, Ph.D., vice president, business development and marketing, will present a corporate overview at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018 (CHIPS) on Friday, March 16, at 3:30 p.m. China Standard Time, 3:30 a.m. Eastern Standard Time, in Hangzhou, China.
The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen's website. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial for recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG. For more information about Tocagen, visit www.tocagen.com.
The Trout Group
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-to-present-at-the-b-riley-fbr-china-healthcare-investment--partnering-symposium-2018-300612703.html
SOURCE Tocagen Inc.